Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The pathogenic oral biofilm matrix and bacterial cell surfaces constitute a complex, three-dimensional environment where microorganisms are encased in a self-produced matrix of extracellular polymeric substances (EPS) (Flemming & Wingender, 2010). This matrix is primarily composed of polysaccharides like glucans and fructans, proteins, and extracellular DNA (eDNA), which provide structural stability and act as a barrier against antimicrobial penetration (Koo et al., 2013). Bacterial cell surfaces within the biofilm display specific adhesins that facilitate attachment to the acquired enamel pellicle and promote inter-species co-aggregation (Marsh, 2004). This structural assembly is a major therapeutic target in dentistry, as it mediates the localized acidification that leads to dental caries and the inflammatory response in periodontitis (Bowden & Hamilton, 1998). Drugs such as chlorhexidine and fluoride interact with these surfaces to disrupt membrane integrity or inhibit the enzymatic production of the matrix (Koo et al., 2017). Effective treatment requires agents that can either degrade the EPS scaffold or interfere with the initial adhesion of bacteria to oral surfaces. Furthermore, the matrix serves as a reservoir for signaling molecules, facilitating quorum sensing and the coordinated expression of virulence factors (Flemming & Wingender, 2010). Targeting the biochemical components of the matrix, such as glucosyltransferases, offers a way to reduce biofilm pathogenicity without necessarily killing all oral bacteria (Koo et al., 2013).
Therapeutic agents targeting the oral biofilm matrix and cell surfaces work through several pathways: physical disruption of the EPS scaffold, enzymatic degradation of matrix polysaccharides (e.g., via dextranases), inhibition of glucosyltransferase enzymes that synthesize the matrix, and the alteration of bacterial cell surface properties to prevent adhesion or induce membrane lysis (Koo et al., 2017; Marsh, 2004).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic oral biofilm matrix and bacterial cell surface.